Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/144391
Title: IDENTIFICATION OF BORTEZOMIB AS MYCOBACTERIAL CASEINOLYTIC PROTEASE INHIBITOR
Authors: GRACE NGAN JIE YIN
Keywords: Bortezomib, Mycobacterium, Caseinolytic Protease, Inhibitor
Issue Date: 4-Jan-2017
Citation: GRACE NGAN JIE YIN (2017-01-04). IDENTIFICATION OF BORTEZOMIB AS MYCOBACTERIAL CASEINOLYTIC PROTEASE INHIBITOR. ScholarBank@NUS Repository.
Abstract: Tuberculosis (TB) diseases remain endemic worldwide. This situation is compounded by the rising of multidrug-resistant TB that calls for an urgent medical need for new drugs with new mechanism of action to control TB diseases. Here, we developed a novel type of antibacterial screen, a target mechanism-based whole-cell screen that used mycobacterial caseinolytic protease proteolytic subunits ClpP1P2 as a target to screen for the inhibitor. A high throughput screen identified Bortezomib, a human proteasome drug, as a potent inhibitor of ClpP1P2-activity and bacterial growth. A plethora of secondary assays demonstrated that Bortezomib indeed exerts its antimicrobial activity via inhibition of ClpP1P2. Characterization of Bortezomib led us to discover that tubercle bacilli and fast-growing mycobacterium evolve different mechanisms of resistance to Bortezomib. This work demonstrates the feasibility of target mechanism-based whole-cell screens, provides chemical validation of ClpP1P2 as a mycobacterial target and identifies Bortezomib as a new lead compound for tuberculosis.
URI: http://scholarbank.nus.edu.sg/handle/10635/144391
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Grace_NJY.pdf6.92 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

48
checked on Sep 18, 2020

Download(s)

20
checked on Sep 18, 2020

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.